查詢結果分析
相關文獻
- Ketoconazole用於治療庫欣氏症候群
- 庫欣氏症候群藥物治療
- The Incidence of Renal Stones in Patients with Cushing's Syndrome
- 庫欣氏症候群
- Role of [fef3]I-NP-59 Adrenal Imaging in Patients of ACTH-Independent Cushing's Syndrome
- 庫欣氏症候群實驗室診斷之介紹
- 醣皮素與醫原性庫欣氏症候群
- Multiple Symmetric Lipomatosis of Madelung-launois-bensaude with Alcoholic Liver Cirrhosis: Report of a Case
- 庫欣氏症候群
- 腎上腺性庫欣氏症候群最新發展
頁籤選單縮合
| 題 名 | Ketoconazole用於治療庫欣氏症候群=Ketoconazole for the Treatment of Cushing's Syndrome |
|---|---|
| 作 者 | 江姿宜; 童玟津; | 書刊名 | 藥學雜誌 |
| 卷 期 | 30:3=120 2014.09[民103.09] |
| 頁 次 | 頁38-43 |
| 分類號 | 418.27 |
| 關鍵詞 | 庫欣氏症候群; 高皮質醇症; Cushing's syndrome; Hypercortisolism; Medical therapy; Ketoconazole; |
| 語 文 | 中文(Chinese) |
| 中文摘要 | 輔助治療庫欣氏症候群 (Cushing's syndrome, CS) 的藥品主要有四大類:腎上腺 酶抑制劑、抑制腎上腺劑、神經調節藥、糖皮質激素受體拮抗劑,其中腎上腺酶抑 制劑 ketoconazole 被建議為第一線用藥。目前美國食品藥物管理局許可 mifepristone (Korlym) 與 pasireotide (Signifor) 用於此適應症。由於單一藥品控制高皮質醇症效果有 限,藉由各藥物之加成或協同作用,採合併療法可減少使用劑量,以降低藥物不良反 應發生之風險。 |
| 英文摘要 | The medical therapy of Cushing's syndrome includes four major categories: adrenal enzyme inhibitors, adrenolytic agents, neuromodulatory drugs, glucocorticoid-receptor antagonists. The adrenal enzyme inhibitors-ketoconazole is recommended as the first drug used. Mifepristone (Korlym) and pasireotide (Signifor) have been approved in the United States by the Food and Drug Administration for this indication. Since limited monotherapy effect of hypercortisolism, the combinations of these drugs often have additive or synergistic therapeutic effects at lower individual doses, thereby minimizing side effects. |
本系統中英文摘要資訊取自各篇刊載內容。